Biotechnology Company Announces Positive Biomarker Data From Major Clinical Trial

NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company known for developing novel treatments for severe neurodegenerative diseases, has recently announced positive 12-month iron biomarker data from its Phase IIb study (PARADIGM). This study evaluated both the safety and efficacy of PrimeC in individuals living with Amyotrophic Lateral Sclerosis (ALS). The newly released data aligns with the company's recent announcements highlighting improved survival rates by 43% and a slowed disease progression by 36%. $NeuroSense Therapeutics (NRSN.US)$